Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Garches – page 123

3 430 clinical trials in Garches, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Garches at a glance
3 430
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 430 trials in Garches

Open in trial search

Homocystinuria

Not yet recruiting

Safety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegtibatinase
  • Sponsor:Travere Therapeutics Inc.

Immunogenicity and safety of RSV A/B prefusion F protein vaccine versus RSV F glycoprotein recombinant adjuvanted vaccine in lung and stem cell transplant recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GSKVx000000017064
  • Sponsor:Hospices Civils De Lyon

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cystic fibrosis

Not yet recruiting

Effect of Stopping Long‑Term Azithromycin in Stable Non‑Cystic Fibrosis Bronchiectasis Patients: A Randomized Controlled Trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Centre Hospitalier Intercommunal Creteil

Appendicitis

Not yet recruiting

Patient‑chosen treatment vs routine surgery for adult uncomplicated acute appendicitis: trial of amoxicillin‑clavulanic acid versus appendectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Myeloproliferative neoplasm

Not yet recruiting

Anakinra for patients with myeloproliferative neoplasms resistant to cytoreductive therapy: a study to improve treatment response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Neoplasm

Not yet recruiting

Study of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Ideaya Biosciences Inc.

Safety and Tolerability of Intrathecal ION337 in Patients with Dravet Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:ION337
  • Sponsor:Ionis Pharmaceuticals Inc.

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib
  • Sponsor:Nuvation Bio Inc.

IPEX syndrome

Not yet recruiting

Safety and Efficacy Study of FOXP3‑T4 and Aldesleukin in Patients with IPEX Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Aldesleukin
  • Sponsor:Assistance Publique Hopitaux De Paris

Relapsing multiple sclerosis+1

Not yet recruiting

Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous Ocrelizumab in Children and Adolescents with Relapsing‑Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Garches

What the registry says about research in the country

01 Neurological Disorders

Clinical trials focusing on innovative treatments for neuromuscular conditions and movement disorders, including studies on Spinal Muscular Atrophy and Myasthenia Gravis. Research examines novel drug delivery systems and therapeutic approaches for improving patient outcomes.

  • Spinal Muscular Atrophy Treatment
  • Myasthenia Gravis Management
  • Myotonic Dystrophy Research
02 Critical Care Medicine

Groundbreaking research in intensive care focusing on treating severe conditions like septic shock and immunosuppression. Studies evaluate new therapeutic approaches for improving survival rates and patient outcomes in critical care settings.

  • Sepsis Treatment Innovations
  • Immune System Support
  • Critical Care Interventions
03 Rare Diseases

Innovative clinical trials targeting rare genetic conditions including Pompe Disease and Fabry Disease. Research focuses on enzyme replacement therapies and novel treatment approaches to improve patient quality of life.

  • Enzyme Replacement Therapy
  • Genetic Disease Management
  • Pediatric Rare Disease Treatment
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.